PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Guardant Health's management is scheduled to present and participate in a Q&A session on Monday, January 12, at 3:45 p.m. Pacific Time / 6:45 p.m. Eastern Time. Interested parties may access live and archived webcasts of the sessions on the “Investors” section.
UPPER NYACK, N.Y.--(BUSINESS WIRE)--Colorectal Cancer Detection Is Primary Goal of Global Healthy Living Foundation and Guardant Health.
Shares of Guardant Health, Inc. (NASDAQ: GH - Get Free Report) have received a consensus rating of "Moderate Buy" from the twenty-four brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and twenty-three have given a buy rating to the company. The average 12-month target price
Shares of Guardant Health, Inc. (NASDAQ: GH - Get Free Report) have received an average rating of "Moderate Buy" from the twenty-four ratings firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation and twenty-three have given a buy recommendation to the company. The average 1-year target
Every once in a while, a secular trend is so obvious that everyone can see it, and that is the case with AI. Drones are another important secular trend that we believe will benefit many areas of the economy. Robots used to be the province of science fiction movies, but today they are an integral and rapidly expanding area of the economy.
Guardant Health, Inc. (NASDAQ: GH - Get Free Report) CTO Darya Chudova sold 5,451 shares of Guardant Health stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $104.04, for a total transaction of $567,122.04. Following the sale, the chief technology officer directly owned 7,012 shares in
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health (Nasdaq: GH), a leading precision oncology company, and Trial Library, an AI technology company enabling oncology clinical trials as a care option, today announced a strategic collaboration to increase access to cancer clinical trials in the United States. The collaboration combines Guardant Health's suite of cutting-edge precision oncology diagnostics with Trial Library's AI-powered matching and patient navigation platform. Together, the comp.
PALO ALTO, Calif. & ROME--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the successful launch of FPG 360, an in-house liquid biopsy testing service at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Policlinico Gemelli) in Rome, Italy. This partnership is the latest in a series of public-private partnerships Guardant Health has formed with top-tier European academic and research hospitals that embed its groundbreaking.
Federated Hermes Inc. lifted its stake in shares of Guardant Health, Inc. (NASDAQ: GH) by 72.4% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,465,438 shares of the company's stock after purchasing an additional 615,429 shares during the quarter. Federated Hermes
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present a total of 14 abstracts with its research collaborators from multiple studies demonstrating the value of its tissue-free liquid biopsy tests at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 9–12, 2025. Oral presentations will highlight results generated with Guardant Reveal, the company's tissue-free test for detecting minimal residual disease (MRD.
